Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEA-CD40 in Advanced Malignancies
NCT02376699Phase 1Terminated
- Sponsor
- Seagen Inc.
- Start
- Feb 2015
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of SEA-CD40 in solid tumor (advanced stage), lymphoma and pancreatic adenocarcinoma (PDAC) (6 arms), sponsored by Seagen Inc. Primary endpoints: Incidence of adverse events, Incidence of laboratory abnormalities and 1 more. Started Feb 2015; status: terminated.
02
Drugs
SEA-CD40
03
Conditions
solid tumor (advanced stage)lymphomapancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02376699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02376699.